Grifols SA operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other pharmaceutical manufacturers in Europe: UCB Sa of BELGIUM (2020 sales of 5.35 billion Euros [US$6.20 billion] of which 34% was Cimzia), Biomerieux SA of FRANCE (3.12 billion Euros [US$3.62 billion] of which 85% was Diagnostic Clinical Equipment), and Lonza Group AG which is based in SWITZERLAND (4.51 billion Swiss Francs [US$4.88 billion] of which 99% was Pharma&Biotech).

Sales Analysis. During the second quarter of 2021, sales at Grifols SA totalled 1.35 billion Euro. This is a drop of 2.3% from the 1.38 billion Euro in sales at the company during the second quarter in 2020. During the first two quarters of 2021, sales totalled 2.54 billion Euro, which is 5.3% lower than through the first two quarters of 2020. Grifols SA reported sales of 5.34 billion Euro (US$6.19 billion) for the year ending December of 2020. This represents an increase of 4.7% versus 2019, when the company's sales were 5.10 billion Euro. Sales at Grifols SA have increased during each of the previous five years (and since 2015, sales have increased a total of 36%). Sales of Others/raw Materials saw an increase that was more than double the company's growth rate: sales were up 40.2% in 2020, from 22.82 million Euro to 31.99 million Euro. Grifols SA also saw significant increases in sales in Bioscience (up 6.2% to 4.24 billion Euro) . Not all segments of Grifols SA experienced an increase in sales in 2020: sales of Bio Supplies fell 15.9% to 224.09 million Euro. Grifols SA also experienced decreases in sales in Hospital (down 11.7% to 118.68 million Euro) .